GST-HG16 / WuXi AppTec, Fujian Cosunter - LARVOL DELTA

[VIRTUAL] First-in-human (FIH) phase I study of GST-HG161, a potent and highly selective c-met inhibitor, in patients with advanced solid tumor. (ASCO 2020) - P1 | "GST-HG161 has been well tolerated to date in study patients with a manageable safety profile. The dose escalation is expected to continue to the proposed 7th cohort at 900 mg. Research Funding: Cosunter Co., Ltd,"

Clinical • P1 data • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer • MET

Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161 (clinicaltrials.gov) - P1; N=62; Recruiting; Sponsor: Fujian Cosunter Pharmaceutical Co. Ltd

Clinical • New P1 trial

Cosunter enrolls first liver patient in phase I study for GST-HG161 (GBI Health) - "China-based Fujian Cosunter Pharmaceutical Co., Ltd, (300436.SZ) announced first patient enrolment for GST-HG161, an innovative liver cancer drug, in a Phase I clinical study in c-MET positive liver cancer. The Phase I study will be extended to evaluate GST-HG161's anti-tumor activity and serve to guide protocol design for a Phase II multi-center clinical trial to be initiated in 2020."

Enrollment open • New P2 trial